News Intercept's Ocaliva approved in EU for liver disease Potential liver blockbuster gets EU licence.
News EU regulator recommends Intercept's potential liver blockbus... Sales forecast to reach $2.6 billion in 2020.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
